Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- Tested for
- Leukemia, Myelomonocytic, Chronic
- Main trialPhase 2
- “The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are: * Does pacritinib improve disease control compared to hydroxyurea? * What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia. Participants will be randomly assigned to receive either…”In the company’s words, NCT07033598 on ClinicalTrials.gov
Other drugs for Leukemia, Myelomonocytic, Chronic
- ASTX030Taiho · Phase 2/3
- ASTX727Taiho · Phase 3
- TuspetinibAptose Biosciences Inc. · Phase 1/2
- BexmarilimabFaron Pharmaceuticals Ltd · Phase 1/2
- S241656Servier · Phase 1/2
- EP0042Ellipses Pharma · Phase 1/2
Coming up1
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2028 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | |
| Phase 2Authorised | not given | Pacritinib For The Reduction Of Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia; A Multicenter, Open-Label, Single Arm, Phase II Exploratory Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026